Myriad Genetics, Inc.
(NASDAQ : MYGN)

( )
MYGN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.05%87.301.3%$1275.26m
AMGNAmgen Inc.
-0.25%198.891.2%$667.61m
GILDGilead Sciences, Inc.
-1.28%67.640.9%$577.79m
BIIBBiogen Inc.
-1.63%332.031.3%$485.41m
LOXOLoxo Oncology Inc
-0.18%233.2612.7%$449.60m
ILMNIllumina, Inc.
0.05%305.633.5%$350.96m
VRTXVertex Pharmaceuticals Incorporated
-0.28%186.151.9%$318.23m
REGNRegeneron Pharmaceuticals, Inc.
-0.12%404.542.6%$308.69m
ALXNAlexion Pharmaceuticals, Inc.
-0.03%111.702.0%$229.47m
TSROTESARO, Inc.
0.03%74.8814.4%$201.67m
AAgilent Technologies, Inc.
-0.82%70.021.5%$164.25m
EXASExact Sciences Corporation
-2.75%74.9725.3%$151.07m
INCYIncyte Corporation
-2.79%76.562.5%$146.84m
SRPTSarepta Therapeutics, Inc.
0.45%119.2615.4%$142.24m
LGNDLigand Pharmaceuticals Incorporated
-16.48%110.0523.1%$105.44m

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through Diagnostics and Other segments. The Diagnostics segment engages in the provision of testing and collaborative development of testing that is designed to asses a risk of developing a disease later in life of an individual. The Other segmeng provides products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.